Roffman Miller Associates Inc. PA Has $630,000 Position in Pfizer Inc. $PFE

Roffman Miller Associates Inc. PA grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,996 shares of the biopharmaceutical company’s stock after buying an additional 4,706 shares during the quarter. Roffman Miller Associates Inc. PA’s holdings in Pfizer were worth $630,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC increased its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer in the 2nd quarter valued at approximately $29,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on PFE shares. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.24.

Pfizer Stock Performance

Shares of Pfizer stock opened at $24.69 on Tuesday. The business has a 50-day simple moving average of $24.76 and a 200 day simple moving average of $24.31. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.14. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $140.40 billion, a price-to-earnings ratio of 13.14, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm posted $0.60 EPS. Pfizer’s revenue was up 10.3% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.